Medtronic Plc

  • Health Care
  • Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • www.medtronic.com
  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $107.73B
  • PE 25
  • Debt $28.33B
  • Cash $1.39B
  • EV $134.67B
  • FCF $5.50B

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$4.29B
EBIT$5.41B
ROE9%
ROA6%
FCF$5.50B
Equity$48.72B
Growth Stability84%
PE25.12
PEG-15.64
PB2.21
P/FCF19.59
P/S3.27
Price/Cash0.01
Debt/Equity0.58
Debt/FCF5.15
Net Margins14%
Gross Margins65%
Op. Margins16%
Earnings CAGR1%
Sales Growth YoY5%
Sales Growth QoQ6%
Sales CAGR1%
FCF CAGR1%
Equity CAGR-0%
Earnings Stability0.01
Earnings Growth YoY40%
Earnings Growth QoQ22%
Earnings CAGR 5Y-2%
Sales CAGR 5Y3%
FCF CAGR 5Y-3%
Equity CAGR 5Y-1%
Earnings CAGR 3Y2%
Sales CAGR 3Y2%
FCF CAGR 3Y-3%
Equity CAGR 3Y-3%
Market Cap$107.73B
Revenue$33.00B
Dividend Yield3%
Payout Ratio85%
Assets$90.04B
Total Debt$28.33B
Cash$1.39B
Shares Outstanding1.28B
EV134.67B
Earnings Score6%
Moat Score85%
Safety Score84%
Final Score58%
Working Capital10.24B
Current Ratio1.84
Gross Profit$21.46B
Shares Growth 3y-1%
Equity Growth QoQ1%
Equity Growth YoY-6%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

SEC Filings

Direct access to Medtronic Plc (MDT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Oct 25
    • 10-Q Jul 26
    • 10-K Apr 26
    • 10-Q Jan 26
  • 2023
    • 10-Q Oct 27
    • 10-Q Jul 28
    • 10-K Apr 28
    • 10-Q Jan 27
  • 2022
    • 10-Q Oct 28
    • 10-Q Jul 29
    • 10-K Apr 29
    • 10-Q Jan 28

Sector Comparison

How does Medtronic Plc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Medtronic Plc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%
Stability 1%
loading chart...

Medtronic Plc Discounted Cash Flow

Fully customizable DCF calculator online for Medtronic Plc.

= $58B
012345678910TV
fcf$5.5B$5.5B$5.6B$5.6B$5.6B$5.7B$5.7B$5.8B$5.8B$5.8B$5.9B$59B
DCF$5B$4.6B$4.2B$3.9B$3.5B$3.2B$3B$2.7B$2.5B$2.3B$23B
Value$58B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years04/201504/201604/201704/201804/201904/202004/202104/202204/202304/2024TTM
Net Margins13%12%14%10%15%17%12%16%12%11%14%
ROA-6%6%7%7%6%5%6%6%6%6%
ROE-7%8%6%9%9%7%10%7%7%9%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years04/201504/201604/201704/201804/201904/202004/202104/202204/202304/2024TTM
Debt over FCF-7.657.277.694.474.65.454.695.375.055.15
Debt over Equity0.710.610.810.550.520.540.520.530.480.520.58
Growth Stability---91%100%100%86%100%84%89%84%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years04/201504/201604/201704/201804/201904/202004/202104/202204/202304/2024CAGR 5Y
Revenue YoY growth-42%3%1%2%-5%4%5%-1%4%3%
Earnings YoY growth-32%14%-23%50%3%-25%40%-25%-2%-2%
Equity YoY growth--2%-3%1%-1%1%1%2%-2%-2%-1%
FCF YoY growth--4%35%-36%62%3%-19%22%-23%14%-3%